Endo sues FDA over its handling of generic Adrenalin approvals
Opioid Qui Tam False Claims Act Case filed by Young Law Group
DUBLIN, Nov. 2, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6 mg capsules, a generic version of Hikma's MITIGARE®. This is the first generic colchicine capsule approved by the U.S. Food and Drug Administration.
DUBLIN, June 12, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine–glycopyrrolate combination product in the U.S.
DUBLIN, June 5, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) in treating men with Peyronie's disease (PD) were published by peer-reviewed journal Urology®. Read the article here.
DUBLIN, May 24, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that its subsidiary Endo Ventures Limited has executed an agreement with MAIA Pharmaceuticals, Inc. to distribute bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial in the U.S. Endo will commercialize the FDA-approved product through its Par Sterile Products business and expects to begin shipping in summer 2023.
Enforcement Report - Week of April 5, 2023
Endo International Plc and Impax Laboratories LLC will face an ordinary class action trial over allegations they schemed to block generic versions of the painkiller Opana ER, a federal judge in Chicago ruled, denying a bid for separate trials of claims by direct and indirect purchasers.
Auxilium Pharms` Biologic Xiaflex Receives Approval in the U.S.
Endo’s last trip to the grocery store enlisted a variety of produce to raise awareness about curved erections in Peyronie’s disease. Now in its first branded campaign for Xiaflex, Endo settles on just one vegetable — a carrot.